Enzyme
Enzyme provides no-code access to Web3 and allows creators and businesses to develop and implement smart contracts. Soon they will let people design smart contract interactions across multiple blockchains. Enzyme is headquartered in United States and was founded in 2020.
Enzyme
Enzyme provides no-code access to Web3 and allows creators and businesses to develop and implement smart contracts. Soon they will let people design smart contract interactions across multiple blockchains. Enzyme is headquartered in United States and was founded in 2020.
TL;DR
Product: No-code platform to create, deploy, and manage smart contracts and web3 apps
Multi-chain support: Supports multiple blockchains and testnets including Ethereum, Polygon, Base, BNB, Optimism, Arweave, Avalanche, Cronos, Arbitrum, Fantom
Go-to-market: Marketplace of pre-built verified smart contracts plus dashboard, minting and sales-page tools
Funding: Seed / early funding reported; public snapshot lists $120,000 total raised (USD) with last funding date 2021-01-25
Company Overview
Problem Domain
Simplifying smart contract development and deployment for creators, brands, and businesses (no-code web3 tooling).
Founded
2020
Industry
Blockchain / Web3
Funding Track Record
$120,000.00
Total funding amount reported in company snapshot
Investor Signal
“Backed by Techstars (noted on company site)”